肺腺癌の新規治療標的としてのCOX5Bを同定する統合的マルチオミクス解析と実験的検証
Lv Ling1, Minying Lu2, Ling Ye3
1Department of Thoracic Surgery, Panyu Hospital of Traditional Chinese Medicine, Guangzhou, 511400, China.
Oncology research
|January 8, 2026
まとめ
肺腺癌(LUAD)におけるシトクロムcオキシダーゼ5B(COX5B)の上昇は、予後不良と相関する。ベルベリンはCOX5Bを標的とし、LUAD細胞の増殖と腫瘍増殖を阻害し、新たな治療戦略を提供する。
科学分野:
- 腫瘍学
- 分子生物学
- 生化学
背景:
- 肺腺癌(LUAD)は依然として課題であり、多くの患者が現在の治療法に抵抗性を示す。
- LUAD治療には、新規予後バイオマーカーおよび治療標度が緊急に必要とされている。
- 本研究では、LUADにおける潜在的な標的としてのシトクロムcオキシダーゼ5B(COX5B)を調査する。
主な方法:
- LUADにおけるCOX5B発現の公開RNAおよびタンパク質データベースの解析。
- COX5Bと免疫浸潤との関係の計算解析。
- 定量的PCR、ウェスタンブロット、免疫組織化学、電子顕微鏡、フローサイトメトリー、EdUアッセイを含む実験的検証。
- ベルベリンがCOX5BおよびLUAD細胞増殖に及ぼす影響の調査。
結論:
- LUAD患者において、アップレギュレーションされたCOX5Bは予後不良の予後指標である。
- ベルベリンはCOX5Bを標的とし、LUAD管理のための新規治療戦略を提供する。
- COX5Bは、LUADの臨床転帰を改善するための有望な治療標的を表す。
関連する概念動画
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K


